Economic burden of toxicities associated with treating metastatic melanoma in the United States

American Health and Drug Benefits

Volumn 9, Issue 4, 2016, Pages 203-212

  Bilir, S Pinar ^a   Ma, Qiufei ^b   Zhao, Zhongyun ^b   Wehler, Elizabeth ^a   Munakata, Julie ^a   Barber, Beth ^b  

^a IQVIA   (United States)

^b AMGEN INC   (United States)

Author keywords

Adverse events; Chemotherapy; Cost analysis; Cost of illness; Dabrafenib; Dacarbazine; Drug related side effects; Interleukin 2; Ipilimumab; Metastatic melanoma; Talimogene laherparepvec; Temozolomide; Toxicities; Trametinib; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANURIA; ARTICLE; CELLULITIS; COLITIS; COMA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG LABELING; DYSPNEA; ECONOMIC EVALUATION; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOPHYSITIS; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NEUTROPENIA; OLIGURIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RASH; SEPSIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

EID: 84976412130     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. National Cancer Institute. SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html. Accessed December 8, 2015.
2. Lin AY, Wang PF, Li H, Kolker JA. Multicohort model for prevalence estimation of advanced malignant melanoma in the USA: an increasing public health concern. Melanoma Res. 2012;22:454-459.
3. Petrella T. Melanoma diagnosis and treatment in Canada. Presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting; April 13-14, 2012; New York, NY. www.hemonctodaymelanoma.com/program12/contents/ pdfs/Saturday/Sat_1525_Petrella_Melanoma_Diagnosis_and_Treatment.pdf. Accessed March 22, 2013.
4. National Cancer Institute. Melanoma treatment-health professional version (PDQ). www.cancer.gov/cancertopics/pdq/treatment/melanoma/Health Professional/page9. Accessed December 11, 2014.
5. US Food and Drug Administration. FDA approves first-of-its-kind product for the treatment of melanoma. Press release. October 27, 2015. www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm. Accessed December 8, 2015.
6. Ascierto PA, Kirkwood JM, Grob J, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85-93.
7. Cancer Research UK. NICE recommends new treatments for advanced melanoma. Press release. November 2, 2012. www.cancerresearchuk.org/can cer-info/news/archive/cancernews/2012-11-01-NICE-recommends-new-treat ments-for-advanced-melanoma. Accessed March 22, 2013.
8. US Food and Drug Administration. Pembrolizumab. www.fda.gov/Drugs/In formationOnDrugs/ApprovedDrugs/ucm412861.htm. Accessed May 10, 2016.
9. US Food and Drug Administration. Nivolumab. www.fda.gov/Drugs/Infor mationOnDrugs/ApprovedDrugs/ucm427807.htm. Accessed May 10, 2016.
10. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
11. Patel PM, Suciu S, Mortier L, et al; For the EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476-1483.
12. Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007; 25:3802-3807.
13. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29:489-498.
14. Flaherty KT, Robert C, Hersey P, et al; For the METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114.
15. Chapman PB, Hauschild A, Robert C, et al; For the BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
16. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723. Erratum in: N Engl J Med. 2010;363:1290.
18. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-2788.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): melanoma. Version 1.2013.
20. Yervoy (ipilimumab) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; March 2011.
21. Zelboraf (vemurafenib) tablet [prescribing information]. South San Francisco, CA: Genentech; August 2011.
22. Tafinlar (dabrafenib) capsules [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2013.
23. Mekinist (trametinib) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2013.
24. Dacarbazine for injection [prescribing information]. North Wales, PA: Teva Pharmaceuticals; 2007.
25. Proleukin (aldesleukin) for injection [prescribing information]. Emeryville, CA: Bayer HealthCare Pharmaceuticals; 2011.
26. Temodar (temozolomide) for injection and capsules [prescribing information]. Whitehouse Station, NJ: Merck; 2013.
27. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
28. US Bureau of Labor Statistics. Consumer Price Index-all urban consumers: 12-month percent change. http://data.bls.gov/timeseries/CUUR0000SAM?output_ view=pct_12mths. Accessed December 11, 2014.
29. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule overview. www.cms.gov/apps/physician-fee-schedule/. Accessed July 9, 2013.
30. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFee Sched/index.html?redirect=/clinicallabfeesched. Accessed July 9, 2013.
31. Wolters Kluwer. Medi-Span Price Rx. https://pricerx.medispan.com/login. aspx. Accessed July 9, 2013.
32. Kaufman HL, Andtbacka RHI, Collichio FA, et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2014;32(15 suppl). Abstract 9008a.
33. Arondekar B, Curkendall SM, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. Value Health. 2013;16. Abstract PCN52.
34. Chang C-L, Schabert VF, Munakata J, et al. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 2015;25: 312-320.
35. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
36. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39.